Yes, congenital adrenal hyperplasia (CAH) is a genetic condition. It follows an autosomal recessive inheritance pattern, meaning a child must inherit one copy of the mutated gene from each parent to develop the condition. About 90 to 95% of cases are caused by mutations in a single gene called CYP21A2, and over 100 different mutations in this gene have been identified.
How CAH Is Inherited
Because CAH is autosomal recessive, both parents must carry at least one copy of a CYP21A2 mutation for their child to be affected. Carriers have one working copy and one mutated copy of the gene, so they typically have no symptoms. When two carriers have a child together, there is a 25% chance the child inherits both mutated copies and develops CAH, a 50% chance the child becomes a carrier like the parents, and a 25% chance the child inherits two working copies.
The gene sits on chromosome 6, right next to a nearly identical but nonfunctional “pseudogene.” This high similarity between the two is part of what makes mutations so common. Segments of DNA can swap between the working gene and the pseudogene during cell division, introducing errors that disable the enzyme the gene is supposed to produce.
What the Gene Actually Does
The CYP21A2 gene provides instructions for making an enzyme called 21-hydroxylase. This enzyme is essential in the adrenal glands, where it helps produce two critical hormones: cortisol (which manages stress and metabolism) and aldosterone (which regulates salt and water balance). When the enzyme doesn’t work properly, the body can’t make enough of these hormones. Hormone precursors build up instead and get redirected into producing androgens, which are male-type sex hormones. The excess androgens are what cause many of CAH’s most recognizable effects.
Mutation Severity Determines the Type of CAH
Not all CYP21A2 mutations are equally damaging, and the severity of the mutation directly determines which form of CAH a person develops. There are two broad categories.
Classic CAH results from mutations that severely reduce or completely eliminate enzyme activity. This is the more serious form, affecting roughly 1 in 15,000 to 20,000 births in Western countries. Infants with classic CAH may have ambiguous genitalia at birth (in girls) or experience life-threatening salt-wasting crises in the first weeks of life if the aldosterone pathway is also affected.
Non-classic CAH is caused by milder mutations that still leave 20 to 50% of enzyme activity intact. It is far more common, occurring in about 1 in 1,000 people in the general population. In certain ethnic groups, the rate climbs to 1 in 100 to 200. Many people with non-classic CAH don’t know they have it until they develop symptoms like early puberty, acne, irregular periods, or difficulty conceiving in adulthood. Some never develop noticeable symptoms at all.
About 12 common mutations account for roughly 95% of all CAH cases. Three of those mutations are specifically linked to the milder, non-classic form.
Ethnic Patterns in CAH Mutations
Different populations tend to carry different CYP21A2 mutations, a pattern that reflects ancestral genetic history. A large study of 716 patients across multiple ethnic groups found striking variation. Among Ashkenazi Jews, a single mutation (V281L) accounted for 63% of affected gene copies, and this mutation is associated with non-classic CAH, which partly explains why non-classic CAH rates are so high in this population. Among Yupik-speaking Eskimos in Western Alaska, only one mutation type was detected across all cases studied.
In Anglo-Saxon populations, large gene deletions were the most common finding at 28% of affected copies. Iranian patients showed one particular splicing mutation in 41% of cases. East Indian populations had a notably higher rate of a severe stop mutation compared to other groups. These patterns matter because they help genetic counselors and labs prioritize which mutations to look for based on a person’s background.
How CAH Is Detected
In most developed countries, newborns are screened for classic CAH within the first few days of life. The screening test measures levels of 17-hydroxyprogesterone (17-OHP) from a small blood sample taken via heel prick. Because 17-OHP is the molecule that builds up when 21-hydroxylase isn’t working, elevated levels signal a problem. If the screening result is abnormal, a repeat blood test and clinical evaluation follow.
Genetic testing confirms the diagnosis and identifies the specific mutations involved. The standard approach combines two laboratory techniques: sequencing (which reads the gene letter by letter to find small errors) and a method called MLPA (which detects larger deletions, rearrangements, or fused genes that sequencing alone would miss). Together, these methods achieve accuracy rates up to 98%.
Non-classic CAH is not caught by newborn screening because 17-OHP levels are not high enough to trigger the test. It is usually diagnosed later in childhood or adulthood when symptoms prompt hormonal testing.
Genetic Testing for Family Planning
If you or your partner carry a CYP21A2 mutation, or if you already have a child with CAH, genetic counseling can clarify the specific risk for future pregnancies. Carrier testing through a blood sample can determine whether each parent carries a mutation and which mutations are present. This information helps predict whether a future child might have classic CAH, non-classic CAH, or simply be a carrier.
For pregnancies identified as high risk, prenatal diagnostic testing can provide a definitive answer. Chorionic villus sampling can be performed between 10 and 13 weeks of pregnancy, offering results earlier than amniocentesis, which is done after 15 weeks. In both procedures, fetal tissue is collected and tested for the specific family mutations. The choice between the two depends on timing and placental position, and both provide definitive genetic diagnosis rather than a probability estimate.
Because CAH follows predictable inheritance rules and the responsible gene is well characterized, families who know their carrier status are in a strong position to make informed reproductive decisions. Knowing the exact mutations each parent carries also helps predict the likely severity of the condition if a child is affected, since milder mutations paired together produce milder disease.